Florey Neurosciences Institute, Centre for Neurosciences, University of Melbourne, Parkville, VIC, Australia.
Cerebellum. 2011 Mar;10(1):81-7. doi: 10.1007/s12311-010-0232-3.
Friedreich's ataxia (FRDA) is the most common early onset inherited ataxia with clinical manifestations, including gradual progression of unremitting cerebellar-sensory ataxia, peripheral sensory loss, loss of lower limb tendon reflexes and hypertrophic cardiomyopathy. Although atrophy of the superior cerebellar peduncle (SCP) has been reported in several magnetic resonance imaging (MRI) studies of FRDA, the relationship of SCP changes to genetic and clinical features of FRDA has not been investigated. We acquired T1-weighted MRI scans in 12 right-handed individuals with FRDA, homozygous for a GAA expansion in intron 1 of FXN, as well as 13 healthy age-matched controls. The corrected cross-sectional areas of the right (left) SCP in the individuals with FRDA (R, 20 ± 7.9 mm(2); L, 25 ± 5.6 mm(2)) were significantly smaller than for controls (R, 68 ± 16 mm(2); L, 78 ± 17 mm(2)) (p < 0.001). The SCP volumes of individuals with FRDA were negatively correlated with Friedreich's ataxia rating scale score (r = -0.553) and disease duration (r = -0.541), and positively correlated with the age of onset (r = 0.548) (p < 0.05). These findings suggest that structural MR imaging of the SCP can provide a surrogate marker of disease severity in FRDA and support the potential role of structural MRI as a biomarker in the evaluation of neurodegenerative diseases and therapies.
弗里德赖希共济失调(FRDA)是最常见的早发性遗传性共济失调,临床表现包括进行性小脑感觉共济失调、周围感觉丧失、下肢腱反射消失和肥厚型心肌病。尽管在 FRDA 的几项磁共振成像(MRI)研究中已经报道了上小脑脚(SCP)的萎缩,但 SCP 变化与 FRDA 的遗传和临床特征之间的关系尚未得到研究。我们在 12 名右手 FRDA 患者(FXN 基因内含子 1 中 GAA 扩展的纯合子)和 13 名年龄匹配的健康对照者中获得了 T1 加权 MRI 扫描。FRDA 患者右侧(左侧)SCP 的校正横截面积(R,20 ± 7.9 mm²;L,25 ± 5.6 mm²)明显小于对照组(R,68 ± 16 mm²;L,78 ± 17 mm²)(p < 0.001)。FRDA 患者的 SCP 体积与 Friedreich 共济失调评定量表评分(r = -0.553)和疾病持续时间(r = -0.541)呈负相关,与发病年龄(r = 0.548)呈正相关(p < 0.05)。这些发现表明,SCP 的结构 MRI 可以提供 FRDA 疾病严重程度的替代标志物,并支持结构 MRI 作为评估神经退行性疾病和治疗方法的生物标志物的潜在作用。